- Home
- JBTM vs CORT Comparison
JBTM vs CORT Comparison
Compare JBTM & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBTM
- CORT
- Stock Information
- Founded
- JBTM 1994
- CORT 1998
- Country
- JBTM United States
- CORT United States
- Employees
- JBTM N/A
- CORT N/A
- Industry
- JBTM
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- JBTM
- CORT Health Care
- Exchange
- JBTM Nasdaq
- CORT Nasdaq
- Market Cap
- JBTM 7.4B
- CORT 7.6B
- IPO Year
- JBTM N/A
- CORT N/A
- Fundamental
- Price
- JBTM $137.57
- CORT $72.87
- Analyst Decision
- JBTM Strong Buy
- CORT Strong Buy
- Analyst Count
- JBTM 2
- CORT 4
- Target Price
- JBTM $143.00
- CORT $139.00
- AVG Volume (30 Days)
- JBTM 458.3K
- CORT 634.6K
- Earning Date
- JBTM 10-21-2025
- CORT 10-29-2025
- Dividend Yield
- JBTM 0.29%
- CORT N/A
- EPS Growth
- JBTM N/A
- CORT N/A
- EPS
- JBTM N/A
- CORT 1.11
- Revenue
- JBTM $2,710,300,000.00
- CORT $716,080,000.00
- Revenue This Year
- JBTM $120.34
- CORT $30.62
- Revenue Next Year
- JBTM $4.52
- CORT $37.68
- P/E Ratio
- JBTM N/A
- CORT $65.48
- Revenue Growth
- JBTM 64.98
- CORT 25.71
- 52 Week Low
- JBTM $85.10
- CORT $35.45
- 52 Week High
- JBTM $148.77
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- JBTM 45.87
- CORT 56.90
- Support Level
- JBTM $135.83
- CORT $67.32
- Resistance Level
- JBTM $141.30
- CORT $72.52
- Average True Range (ATR)
- JBTM 3.28
- CORT 2.19
- MACD
- JBTM -1.04
- CORT 0.36
- Stochastic Oscillator
- JBTM 14.07
- CORT 74.30
About JBTM JBT Marel Corporation
JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.